Beyond Clozapine: The Cardiac Threat Hiding Across Antipsychotics

Key Takeaway: A comprehensive review reveals that the risk of myocarditis and cardiomyopathy, long associated primarily with clozapine, extends to many commonly prescribed antipsychotics, including quetiapine and olanzapine. Clinicians treating patients with any antipsychotic must maintain a high index of suspicion for cardiac symptoms like unexplained fatigue, chest pain, or shortness of breath, especially during treatment initiation or dose changes.

A Danger Hiding in Plain Sight

A well-known cardiac danger of a powerful psychiatric medication may be just the tip of the iceberg. For decades, clozapine, the gold standard for treatment-resistant schizophrenia, has carried a reputation for causing cardiac problems. Prescribers know the drill: mandatory blood monitoring, careful titration, and a vigilant watch for signs of myocarditis, a potentially fatal inflammation of the heart muscle. However, a new review of the broader antipsychotic class warns that we may have focused so intently on clozapine that we have overlooked the same threat lurking behind some of the world’s most frequently prescribed psychiatric drugs.

The significance of this cannot be overstated. Quetiapine and olanzapine are not niche medications. Quetiapine alone is among the most commonly prescribed psychiatric drugs in the United States, used increasingly not just for schizophrenia and bipolar disorder, but also for insomnia, anxiety, and as an augmentation strategy for depression^[2]. If even a small fraction of these millions of prescriptions carries a meaningful cardiac risk, the public health implications are immense.

Findings of the Review

This review synthesized evidence from pharmacovigilance databases, case reports, and preclinical studies to paint a comprehensive picture of antipsychotic-associated myocarditis and cardiomyopathy, a condition where the heart muscle weakens and cannot pump blood effectively. The findings paint a sobering picture.

Clozapine remains the most dangerous agent, with a reported myocarditis incidence ranging from 0.3% to 3% of exposed patients^[1]. While this rate may seem small, it is alarming for a condition that can cause sudden heart failure and death in otherwise healthy young patients. But what makes this review a true wake-up call is what it found beyond clozapine. Pharmacovigilance data—large-scale adverse event reporting systems that serve as medicine’s early warning radar—show consistent secondary signals for both quetiapine and olanzapine. These are not isolated case reports; they represent a pattern of harm emerging from real-world use across diverse populations.

The review also identified weaker but present associations for risperidone, aripiprazole, and several other antipsychotic agents. The proposed mechanisms suggest this is not an idiosyncratic feature of one molecule but may be a class-wide vulnerability rooted in the fundamental biology of how these drugs interact with heart tissue.

How Antipsychotics May Harm the Heart

Understanding the mechanism behind antipsychotic cardiotoxicity requires a brief look at cardiac biology. The heart is an exceptionally energy-hungry organ. Each heart muscle cell—or cardiomyocyte—is packed with mitochondria, the tiny organelles that produce the chemical fuel (adenosine triphosphate, or ATP) that powers every heartbeat^[3]. Anything that disrupts mitochondrial function threatens the heart’s ability to contract reliably.

The review identifies three overlapping pathways through which antipsychotics appear to damage the myocardium. First is a hypersensitivity reaction, where the immune system essentially launches an allergic-type response to the drug, with the heart as collateral damage. This mechanism is best characterized with clozapine, where biopsies have documented eosinophilic infiltration of the heart muscle^[4]. The second pathway involves inflammatory cytokine activation. Antipsychotics can trigger the release of signaling molecules like interleukin-6 and tumor necrosis factor-alpha, which, in excess, can directly damage cardiomyocytes and promote fibrosis—scarring that stiffens the heart wall and impairs its pumping function^[5].

The third mechanism—mitochondrial dysfunction—may be the most insidious. Preclinical data show that certain antipsychotics disrupt the electron transport chain within cardiac mitochondria, effectively starving the cell of energy and producing toxic reactive oxygen species that damage proteins and DNA^[6]. Unlike a hypersensitivity reaction, which tends to manifest early and dramatically, mitochondrial damage can accumulate silently over months or years, eventually presenting as dilated cardiomyopathy—a weakened, enlarged heart that struggles to keep up with the body’s demands.

This trifecta of damaging pathways helps explain why the risk is not confined to a single drug. Different antipsychotics may trigger different combinations of these mechanisms at varying intensities, but the final outcome—a damaged heart—can look remarkably similar.

Notable Limitations

No single review rewrites the medical textbooks. Narrative reviews, by their nature, synthesize existing evidence rather than generating new data and are subject to selection bias in which studies are included. Much of the pharmacovigilance signal for quetiapine and olanzapine comes from spontaneous adverse event reports, which are notoriously prone to underreporting and confounding factors. Patients taking antipsychotics often have metabolic syndrome, smoke heavily, and are on multiple medications, all of which independently increase cardiac risk^[7]. Teasing out the direct effect of the drug from this background risk is extraordinarily difficult without large, well-controlled prospective studies that do not yet exist.

Conclusion: Practical Implications for Patients

The review’s central recommendation is both simple and urgent: extend cardiac vigilance beyond clozapine. The authors call for a risk-stratified approach, meaning patients with pre-existing heart conditions, metabolic syndrome, or a history of cardiac symptoms should be monitored more closely when starting or adjusting the dose of any antipsychotic, not just clozapine.

In recent months, a psychiatrist referred a young patient to me who was on clozapine for severe psychosis and complaining of palpitations. I examined the patient and ran tests. Indeed, there were signs of myocarditis that I believed were linked to the clozapine. I explained to the patient’s mother, who was present, that this condition was a result of the medication and that his cardiac symptoms would likely improve significantly if it were discontinued. The pleading look in that mother’s eyes still comes to mind. I had the patient go to the waiting room and spoke with his mother again. She told me her son had attempted suicide twice, had tried numerous medications, and had benefited most from clozapine. I was now faced with a dilemma: continuing the drug would pose a risk for myocarditis. I had to give the mother an answer. Ultimately, I called the patient’s psychiatrist, who confirmed the mother’s account. However, this drug could pose a vital risk over time. I discussed the issue in detail with my colleague. I started a treatment to protect the heart, and the psychiatrist recommended a dose adjustment and a new treatment combination. In our intermittent follow-ups, the patient is doing well for now. I hope he continues to do so.

In practice, this means that any patient who develops unexplained fatigue, new-onset shortness of breath, a rapid heart rate, or chest discomfort after starting or increasing the dose of an antipsychotic deserves an urgent evaluation. Targeted biomarker testing—specifically troponin levels (a protein released when heart muscle cells are damaged) and B-type natriuretic peptide (BNP, a marker of heart strain)—can help catch myocarditis and cardiomyopathy before they become life-threatening. In this context, echocardiography should not be forgotten either ^[8]. Careful, slow titration, especially during the first few weeks of treatment when hypersensitivity reactions are most likely, is another practical measure.

For the millions of people who rely on antipsychotic medications to manage devastating psychiatric illnesses, this is not a reason to panic or stop treatment. But it is a reason for vigilance—and a reason for every prescriber, whether a psychiatrist or a primary care physician, to listen a little more closely when a patient on quetiapine says, “I just don’t feel right.”

Scientific Sources

1. Sarangal M, et al. Beyond Clozapine: Myocarditis and Cardiomyopathy Associated with Antipsychotic Medications-An Updated Narrative Review for Psychiatric Practice. Psychopharmacology bulletin. 2026;56(3):124-129. PubMed: https://pubmed.ncbi.nlm.nih.gov/42267232/
2. Alexander GC, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-184.
3. Kolwicz SC Jr, et al. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013;113(5):603-616.
4. Haas SJ, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007;30(1):47-57.
5. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91(11):988-998.
6. Varga ZV, et al. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(9):H1453-H1467.
7. Correll CU, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
8. Ronaldson KJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458-465.